Arginine-Based Poly(I:C)-Loaded Nanocomplexes for the Polarization of Macrophages Toward M1-Antitumoral Effectors.
Dacoba TG
Front Immunol. 2020 Jul 7;11:1412. doi: 10.3389/fimmu.2020.01412
Therapeutic Manipulation of Tumor-associated Macrophages: Facts and Hopes from a Clinical and Translational Perspective.
Allavena P
Clin Cancer Res. 2021 Feb 2;27(12):3291-3297. doi: 10.1158/1078-0432.CCR-20-1679
Optimization of a Luciferase-Expressing Non-Invasive Intrapleural Model of Malignant Mesothelioma in Immunocompetent Mice.
Digifico E
Cancers (Basel). 2020 Aug 1;12(8)doi: 10.3390/cancers12082136
The soluble glycoprotein NMB (GPNMB) produced by macrophages induces cancer stemness and metastasis via CD44 and IL-33.
Liguori M
Cell Mol Immunol. 2020 Jul 29;18(3):711-722. doi: 10.1038/s41423-020-0501-0
Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity.
Anfray C
J Immunother Cancer. 9(9)doi: 10.1136/jitc-2021-002408
Mannose-modified hyaluronic acid nanocapsules for the targeting of tumor-associated macrophages.
Fernández-Mariño I
Drug Deliv Transl Res. 2022 Dec 6;13(7):1896-1911. doi: 10.1007/s13346-022-01265-9
Oncogenic KRAS-Induced Protein Signature in the Tumor Secretome Identifies Laminin-C2 and Pentraxin-3 as Useful Biomarkers for the Early Diagnosis of Pancreatic Cancer.
Kamal MA
Cancers (Basel). 2022 May 27;14(11)doi: 10.3390/cancers14112653
Size-advantage of monovalent nanobodies against the macrophage mannose receptor for deep tumor penetration and tumor-associated macrophage targeting.
Erreni M
Theranostics. 2023 Jan 1;13(1):355-373. doi: 10.7150/thno.77560
Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy.
Aiuti A
J Clin Invest. 117(8):2233-40.
Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients.
Cassani B
Blood. 2008 Jan 24;111(8):4209-19. doi: 10.1182/blood-2007-05-092429